Evoke Receives FDA Conditional Acceptance of Gimoti Brand Name Following NDA Resubmission Read more about Evoke Receives FDA Conditional Acceptance of Gimoti Brand Name Following NDA Resubmission
Evoke Pharma Reports First Quarter 2020 Financial Results and Changes its 2020 Annual Meeting of Stockholders to a Virtual Format Read more about Evoke Pharma Reports First Quarter 2020 Financial Results and Changes its 2020 Annual Meeting of Stockholders to a Virtual Format
Evoke Pharma Reports Fourth Quarter and Full Year 2019 Financial Results Read more about Evoke Pharma Reports Fourth Quarter and Full Year 2019 Financial Results
Evoke Pharma Receives Notice of Allowance from USPTO for Gimoti™ Read more about Evoke Pharma Receives Notice of Allowance from USPTO for Gimoti™
Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™ Read more about Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™
FDA Accepts Evoke Pharma’s NDA Resubmission for Gimoti™ Read more about FDA Accepts Evoke Pharma’s NDA Resubmission for Gimoti™
Evoke Resubmits Gimoti™ New Drug Application to FDA Read more about Evoke Resubmits Gimoti™ New Drug Application to FDA
Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement Read more about Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement
Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price Read more about Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price
Evoke Pharma Reports Third Quarter 2019 Financial Results Read more about Evoke Pharma Reports Third Quarter 2019 Financial Results